Acura Pharmaceuticals

Focus: Acura Pharmaceuticals specializes in abuse-deterrent formulations for opioid medications, addressing a critical public health need in pain management. The company operates as a focused specialty pharmaceutical player based in Palatine, Illinois.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Acura Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Acura Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

hydrocodone bitartrate/acetaminophen

Opioid-Related Disorders

Phase 2

Clinical Trials (1)

NCT01759446Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users

Phase 2

Help build intelligence for Acura Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused mission in abuse-deterrent technology addresses a high-priority regulatory and public health landscape with strong tailwinds
Pipeline includes Phase 3 oxycodone/niacin program with 2 active trials, signaling near-term catalysts and regulatory momentum
Neurology therapeutic focus provides depth in a well-established therapeutic area with clear unmet needs in pain management

Watch Out For

No active job openings listed, indicating potential hiring freeze or limited growth trajectory
Minimal publicly disclosed financial data, R&D spend, or cash position raises uncertainty about company stability and runway

Generated by Claude from Acura Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Acurox 5/30mg taken first

Opioid Abuse

Phase 2

Clinical Trials (1)

NCT00699010Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse

Phase 2

40/0mg taken first

Opioid Abuse

Phase 2

oxycodone/niacin

Pain

Phase 3